Zusammenfassung
73-jährige Patientin mit einem BMI von 34, einer gut eingestellten arteriellen Hypertonie, einem LDL von 168 mg/dl und einer gestörten Glukosetoleranz kommt zur Lebensstilberatung, um durch Lebensstiländerung den manifesten Diabetes und kardiovaskuläre Erkrankungen zu vermeiden. Was kann man raten?
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290(4):486–494
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685–696
Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374):2005–2016
Diabetes Prevention Program Research Group (2015) Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 3(11):866–675
Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO (2007) Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care 30(10):2478–2483
Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, Yang W, Zhang B, Shuai Y, Hong J, Engelgau MM, Li H, Roglic G, Hu Y, Bennett PH (2014) Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2(6):474–480
Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371(9626):1783–1789
Look AHEAD Research Group (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369(2):145–154
Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes (2014) 1. Auflage, Version 4, 2014
Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M (2015) Excess mortality among persons with type 2 diabetes. N Engl J Med 373(18):1720–1732
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Fischer, A., Nawroth, P. (2018). Fall 33: Prävention – 73 Jahre, ♀, Prädiabetes, Übergewicht, gestörte Glukosetoleranz. In: Kihm, L., Kopf, S., Nawroth, P. (eds) Diabetes-Therapie – informiert entscheiden. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-55972-7_33
Download citation
DOI: https://doi.org/10.1007/978-3-662-55972-7_33
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-55971-0
Online ISBN: 978-3-662-55972-7
eBook Packages: Medicine (German Language)